Dianthus Therapeutics, INC /DE/

Dianthus Therapeutics announced a 75% responder rate in the interim analysis of its Phase 3 CAPTIVATE trial for claseprubart in CIDP.

Dianthus Therapeutics stockholders re-elected three Class II directors and ratified the appointment of Deloitte & Touche as auditor.

Dianthus Therapeutics announced Q1 2026 financial results, highlighting progress in clinical trials for claseprubart and DNTH212, and a strengthened balance sheet.

Dianthus Therapeutics, Inc. announced FDA agreement to modify screening criteria and risk classification for its claseprubart clinical trials, alongside an updated corporate presentation highlighting strong financial position and pipeline progress.

Dianthus Therapeutics successfully completed a public offering of common stock and pre-funded warrants, raising approximately $673.5 million in net proceeds.

Dianthus Therapeutics reports a robust cash position of $514 million and positive Phase 2 results for its lead candidate, claseprubart, in generalized myasthenia gravis.

Dianthus Therapeutics reports significant cash increase following a large public offering, advances clinical trials for claseprubart and DNTH212, and maintains sufficient funding into 2030.

Dianthus Therapeutics announces positive Phase 2 data for claseprubart in gMG, licenses new bifunctional inhibitor DNTH212, and secures $288.4 million in public offering proceeds, extending cash runway into 2028.

Dianthus Therapeutics reported a significant increase in net loss and R&D expenses for the first half of 2025, driven by advancing clinical trials for its lead candidate, claseprubart, while maintaining a cash runway into late 2027.

Dianthus Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its clinical trials and providing an update on its financial position.

Dianthus Therapeutics reported a net loss of $25.2 million for the third quarter of 2024, alongside updates on clinical trials and financial activities.

Dianthus Therapeutics, a clinical-stage biotechnology company, released its second quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Dianthus Therapeutics continues to advance its clinical-stage complement therapeutic, DNTH103, while reporting a net loss of $85.0 million for the year ended December 31, 2024.

Dianthus Therapeutics' 10-K filing details its capital stock structure, anti-takeover provisions, and regulatory compliance, highlighting its focus on developing complement therapeutics.

Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, Inc. /DE/, sold 31,249 shares of common stock on July 9, 2026.

Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, Inc., reported transactions involving the purchase and sale of company common stock on June 17, 2026, executed under a Rule 10b5-1 trading plan.

EVP and Head of R&D Simrat Randhawa exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Director Simon Read was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of an equity compensation award.

Director Steven J. Romano was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of an equity incentive.

Director Anne McGeorge was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of a standard equity compensation award.

Dianthus Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on May 21, 2026, to elect directors, vote on executive compensation, and ratify auditor appointments.

Dianthus Therapeutics announces its annual stockholder meeting to be held on May 22, 2025, with proxy materials available online.

Dianthus Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 22, 2025, featuring director elections, executive compensation advisory vote, and ratification of the independent accounting firm.

Dianthus Therapeutics will hold its annual stockholder meeting on May 23, 2024, to vote on director elections, executive compensation, and other key proposals.

Dianthus Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on May 23, 2024, featuring proposals including director elections, executive compensation, and ratification of the independent accounting firm.

Dianthus Therapeutics files an amendment to its S-1 registration statement to register the resale of common stock by selling stockholders.

Dianthus Therapeutics amends its S-1 registration statement to register the resale of up to 21,326,988 shares of common stock by selling stockholders.

Fairmount Funds Management LLC and its affiliates have reduced their beneficial ownership in Dianthus Therapeutics, Inc. to below 5%, marking an exit filing.

Avidity Partners Management LP and its affiliates have reduced their beneficial ownership in Dianthus Therapeutics, Inc. to below 5%, filing an exit amendment to their Schedule 13D.

Fairmount Funds Management and its affiliates increased their beneficial ownership in Dianthus Therapeutics to 9.9% following a $19.8 million share purchase.

Avidity Partners Management LP and its affiliates have filed an Amendment No. 2 to Schedule 13D, reporting a decrease in their beneficial ownership of Dianthus Therapeutics, Inc. common stock to 9.9% following a significant share sale.

Point72 Asset Management and Steven A. Cohen have reported a 1.2% beneficial ownership stake in Dianthus Therapeutics, Inc. as of March 31, 2026.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 5.3% of Dianthus Therapeutics, Inc. common stock.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 4.8% of Dianthus Therapeutics, Inc. common stock as of March 31, 2026.

Octagon Capital Advisors LP and affiliated entities have reported beneficial ownership of 3.6% of Dianthus Therapeutics, Inc. common stock as of March 31, 2026.

BlackRock, Inc. has reported beneficial ownership of 5.1% of Dianthus Therapeutics Inc.'s common stock as of March 31, 2026.

Octagon Capital Advisors LP and its affiliates, including Ting Jia, have reported a 6.1% beneficial ownership stake in Dianthus Therapeutics, Inc. common stock.